Chosa Oncology (CHOSA) Q4 2024 earnings summary

Executive summary

• Focused on precision oncology, CHOSA advances its Cisplatin-DRP technology and LiPlaCis drug candidate, targeting improved cancer treatment outcomes and reduced toxicity.

• Strategic collaborations with leading oncologists and European lung cancer experts aim to validate and integrate CHOSA's solutions into clinical guidelines.

• Professor Fred Hirsch, a renowned lung cancer expert, joined the board, strengthening clinical and scientific leadership.

Financial highlights

• Full-year 2024 result after financial items: -9,594 TSEK (improved from -23,752 TSEK year-over-year).

• Q4 2024 result after financial items: -4,303 TSEK (vs. -1,859 TSEK in Q4 2023).

• Earnings per share after dilution: -0.14 SEK for 2024 (vs. -0.37 SEK in 2023); Q4: -0.06 SEK (vs. -0.03 SEK).

• Cash and cash equivalents at year-end: 6,438 TSEK (down from 8,772 TSEK at prior year-end).

• Equity at year-end: 13,817 TSEK (down from 17,411 TSEK).

Outlook and guidance

• Ongoing efforts to secure commercial partners for licensing, sales, or collaboration to bring products to market.

• Plans for targeted new share issues or other capital-raising measures to support strategic execution.

• Continued focus on clinical validation, regulatory progress, and expansion of strategic partnerships.